NICE recommends Lenvima for advanced liver cancer
The National Institute for Health and Care excellence (NICE) has recommended Eisai and MSD’s Lenvima, a potentially life-extending treatment for adults with advanced liver cancer.
Read More
Tag: lenvatinib
Lenvima backed for NHS use to treat liver cancer
NICE has issued draft guidelines backing use of Eisai/MSD’s Lenvima on the NHS in England and Wales as an option for a type of untreated, advanced liver cancer.
Read More
Eisai/MSD’s Lenvima approved in Europe for liver cancer
Eisai and MSD’s Lenvima has won approval in the EU as a first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Read More
Lenvima wins green light in liver cancer
Eisai and MSD’s Lenvima (lenvatinib) has been approved in the US for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Read More
US ‘breakthrough’ badge for MSD/Eisai cancer combo
A combination therapy being developed by MSD and Eisai for kidney cancer has been awarded Breakthrough Designation in the US.
Read More
NICE u-turn backs combo for kidney cancer
In a turnaround from its earlier position, the National Institute for Health and Care Excellence is now endorsing NHS funding for Eisai’s Kisplyx plus everolimus for kidney cancer.
Read More
NICE bars NHS access to Lenvima, Nexavar for thyroid cancer
NHS treatment cost regulators have published draft guidelines rejecting funding for Eisai’s Lenvima and Bayer’s Nexavar for treating certain patients with thyroid cancer.
Read More
NICE turns down kidney cancer drugs
It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
Read More
US, EU filings for Eisai’s lenvatinib in liver cancer
Eisai has filed its anticancer drug lenvatinib for liver cancer on both sides of the Atlantic as it seeks to expand the drug’s list of approved uses.
Read More
Eisai’s Lenvima hits liver cancer targets in PhIII trial
A late-stage trial assessing Eisai’s cancer drug Lenvima for hepatocellular carcinoma (HCC) has achieved its primary endpoint, pushing the drug closer to being filed for approval in this setting.
Read More
Eisai’s Kisplyx approved in EU for kidney cancer
The European Commission has stamped its approval on the use of Eisai’s Kisplyx to treat advanced kidney cancer.
Read More
Eisai, NHS and NICE fail to reach deal on Lenvima
Patients with an advanced form thyroid cancer may have to wait three years for NHS access to Eiasai’s Lenvima in England, after the drug was left out of the newly launched Cancer Drugs Fund.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
